Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine added to stimulants in children with ADHD
IRCT20200825048515N58Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of memantine in attention deficit hyperactivity disorder (ADHD), sponsored by Isfahan University of Medical Sciences. Started Sep 2022; status: completed.
02
Drugs
memantine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20200825048515N58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N58.